FDA approves first gene therapy for paediatric spinal muscular atrophy
The FDA has given approval to AveXis for the first treatment of paediatric spinal muscular atrophy (SMA).
List view / Grid view
The FDA has given approval to AveXis for the first treatment of paediatric spinal muscular atrophy (SMA).
24 June 2015 | By Victoria White
EMA grants Orphan Drug designation to AveXis' gene transfer therapeutic currently in clinical development for the treatment of spinal muscular atrophy...